Note: Due to the number of Tweets embedded in this post the page may take some time to load.
Saturday was a busy day at #ASCO23. For me it included live sessions, on-demand sessions and two meetings.
Opening Session
Dr. Eric Winer @ASCOPres shares lessons learned from his powerful personal story
— Stephanie Graff, MD, FACP (@DrSGraff) June 3, 2023
1️⃣relationship w/healthcare team is paramount
2️⃣Science matters
3️⃣We all face challenges
4️⃣Response to illness vary individually
5️⃣Stigma can be crushing #ASCO23 @OncoAlert pic.twitter.com/zvwTZREosv
@NCIDirector , Opening Session #ASCO23 #gyncsm pic.twitter.com/tlPXYjvjd2
— Dee Sparacio (@womenofteal) June 3, 2023
The session finished with a chat with the Surgeon General, Dr Vivak Murphy who discussed a range of topics.
Case-based Panel - GTD
This session which talked about a Gestational Trophoblastic Disease ( GTD) a rare gyn cancer. I viewed on-demand the day after the presentation.
2/2 Watching Session On Demand "Rare Gynecologic Cancers: A Case of Gestational Trophoblastic Neoplasia" from 6/3 #ASCO23 #gyncsm Treatments Learned so much from this session. pic.twitter.com/Ag4Mvb1X6c
— Dee Sparacio (@womenofteal) June 4, 2023
Oral Abstract Session
Cervical Cancer - Keynote 826
🙌 KEYNOTE826 - longer OVERALL SURVIVAL for patients w/ recurrent #CervicalCancer who received pembrolizumab +/- bevacizumab in combination with chemotherapy #ASCO23 #gyncsm #ImmunoOnc
— Shannon Westin (@ShannonWestin) June 3, 2023
💯 STANDARD OF CARE pic.twitter.com/QPYSH6tuag
Ovarian cancer
Ofranergene obadenove + weekly taxol
😔 Ofranergene obadenovec (VB-1111) added to weekly paclitaxel in recurrent platinum-resistant #OvarianCancer did not improve progression free or overall survival
— Shannon Westin (@ShannonWestin) June 3, 2023
🚨 This area remains a clear unmet need #ASCO23 #gyncsm pic.twitter.com/mzZNLKnUEO
Rebecca Arend: Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).
— Annie Ellis (@Stigetta) June 3, 2023
#ASCO23 #gyncsm pic.twitter.com/CzYvxvTkHa
GOG 3025 -durvalumab + olaparib + bevacizumab
🚨Another practice-changing study at #ASCO23
— Shannon Westin (@ShannonWestin) June 3, 2023
🌟DUO-O/@GOG 3025 demonstrates improved progression free survival in pts w/ HR deficient AND proficient advanced stage #OvarianCancer treated with durvalumab + olaparib + bevacizumab #gyncsm #ImmunoOnc pic.twitter.com/r6BSrQEWyk
Luveltamab tazevibulin (STRO-002)
Ana Oaknin: Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety & efficacy in a broad distribution of FolRα exp in pts w/ recurrent ovarian cancer (OC): Update of STRO-002-GM1 P 1 dose expansion cohort. #ASCO23 #gyncsm pic.twitter.com/yqaXYDFhEh
— Annie Ellis (@Stigetta) June 3, 2023
Endometrial Cancer
Camrelizumab (PD-1i) and apatinib (VEGFR2i) active in recurrent #EndometrialCancer
— Shannon Westin (@ShannonWestin) June 3, 2023
👍 44% overall response rate
✅91% disease control rate
⚠️ Important! All patients were #Immunotherapy naive - so appears similar to LEN/PEM in this space#ASCO23 #gyncsm #ImmunoOnc pic.twitter.com/aydsO5G00U
Did I miss any important gyn studies? Please note them in the comment box. Thanks
Check back tomorrow for highlights from Day 3.
Dee
Every Day is a Blessing!
No comments:
Post a Comment